| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ORGO | Class A Common Stock | Options Exercise | $24,070 | +24,313 | +18% | $0.9900 | 156,230 | 16 Jul 2021 | Direct | |
| transaction | ORGO | Class A Common Stock | Options Exercise | $466,418 | +115,450 | +74% | $4.04 | 271,680 | 16 Jul 2021 | Direct | |
| transaction | ORGO | Class A Common Stock | Sale | $1,608,597 | -110,329 | -41% | $14.58 | 161,351 | 16 Jul 2021 | Direct | F1, F2 |
| transaction | ORGO | Class A Common Stock | Sale | $451,223 | -29,434 | -18% | $15.33 | 131,917 | 16 Jul 2021 | Direct | F1, F3 |
| transaction | ORGO | Class A Common Stock | Options Exercise | $158,635 | +160,237 | +121% | $0.9900 | 292,154 | 19 Jul 2021 | Direct | |
| transaction | ORGO | Class A Common Stock | Sale | $2,246,523 | -160,237 | -55% | $14.02 | 131,917 | 19 Jul 2021 | Direct | F1, F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ORGO | Stock Option (Right to Buy) | Options Exercise | $0 | -24,313 | -3.5% | $0.000000 | 680,097 | 16 Jul 2021 | Class A Common Stock | 24,313 | $0.9900 | Direct | F5 |
| transaction | ORGO | Stock Option (Right to Buy) | Options Exercise | $0 | -115,450 | -20% | $0.000000 | 465,392 | 16 Jul 2021 | Class A Common Stock | 115,450 | $4.04 | Direct | F6 |
| transaction | ORGO | Stock Option (Right to Buy) | Options Exercise | $0 | -160,237 | -24% | $0.000000 | 519,860 | 19 Jul 2021 | Class A Common Stock | 160,237 | $0.9900 | Direct | F5 |
| Id | Content |
|---|---|
| F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2021. |
| F2 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $14.27 to $14.99, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. |
| F3 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.85, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. |
| F4 | The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.61 to $14.38, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. |
| F5 | 100% of the shares subject to the option are fully vested and exercisable. |
| F6 | The option became and continues to become exercisable in equal annual installments over four years beginning April 1, 2020. |